Tags

Type your tag names separated by a space and hit enter

The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes.
J Clin Endocrinol Metab. 2015 Aug; 100(8):3126-31.JC

Abstract

CONTEXT

IGF-I is thought to mediate many of the anabolic actions of GH, and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance.

OBJECTIVE

The objective of the study was to investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes.

DESIGN AND SETTING

This was a randomized, double-blind, placebo-controlled recombinant human (rh) IGF-I/rhIGF binding protein (IGFBP)-3 administration study at Southampton General Hospital (Southampton, United Kingdom).

PARTICIPANTS

Fifty-six recreational athletes (30 men, 26 women) participated in the study.

INTERVENTION

Participants were randomly assigned to receive placebo, low-dose rhIGF-I/rhIGFBP-3 (30 mg/d), or high dose rhIGF-I/rhIGFBP-3 (60 mg/d) for 28 days. Body composition (assessed by dual energy x-ray absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test) were measured before and immediately after treatment. Within-individual changes after treatment were analyzed using paired t tests.

RESULTS

There were no significant changes in body fat mass or lean body mass in women or men after the administration of the rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low- and high-dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = .001). No significant change in VO2 max was observed in the placebo group.

CONCLUSIONS

rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes, but there are no effects on body composition.

Authors+Show Affiliations

Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.Human Development and Health Academic Unit (N.G., S.P.N., M.F., J.A.W., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton SO16 6YD, and University Hospital Southampton, National Health Service Foundation Trust SO16 6YD, and Southampton Statistical Sciences Research Institute (D.B.), University of Southampton, Southampton SO17 1BJ, United Kingdom.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26046967

Citation

Guha, Nishan, et al. "The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration On Body Composition and Physical Fitness in Recreational Athletes." The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 8, 2015, pp. 3126-31.
Guha N, Nevitt SP, Francis M, et al. The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes. J Clin Endocrinol Metab. 2015;100(8):3126-31.
Guha, N., Nevitt, S. P., Francis, M., Woodland, J. A., Böhning, D., Sönksen, P. H., & Holt, R. I. (2015). The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes. The Journal of Clinical Endocrinology and Metabolism, 100(8), 3126-31. https://doi.org/10.1210/jc.2015-1996
Guha N, et al. The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration On Body Composition and Physical Fitness in Recreational Athletes. J Clin Endocrinol Metab. 2015;100(8):3126-31. PubMed PMID: 26046967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes. AU - Guha,Nishan, AU - Nevitt,Simon P, AU - Francis,Michael, AU - Woodland,John A, AU - Böhning,Dankmar, AU - Sönksen,Peter H, AU - Holt,Richard I G, Y1 - 2015/06/05/ PY - 2015/6/6/entrez PY - 2015/6/6/pubmed PY - 2015/11/18/medline SP - 3126 EP - 31 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 100 IS - 8 N2 - CONTEXT: IGF-I is thought to mediate many of the anabolic actions of GH, and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance. OBJECTIVE: The objective of the study was to investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes. DESIGN AND SETTING: This was a randomized, double-blind, placebo-controlled recombinant human (rh) IGF-I/rhIGF binding protein (IGFBP)-3 administration study at Southampton General Hospital (Southampton, United Kingdom). PARTICIPANTS: Fifty-six recreational athletes (30 men, 26 women) participated in the study. INTERVENTION: Participants were randomly assigned to receive placebo, low-dose rhIGF-I/rhIGFBP-3 (30 mg/d), or high dose rhIGF-I/rhIGFBP-3 (60 mg/d) for 28 days. Body composition (assessed by dual energy x-ray absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test) were measured before and immediately after treatment. Within-individual changes after treatment were analyzed using paired t tests. RESULTS: There were no significant changes in body fat mass or lean body mass in women or men after the administration of the rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low- and high-dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = .001). No significant change in VO2 max was observed in the placebo group. CONCLUSIONS: rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes, but there are no effects on body composition. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/26046967/The_Effects_of_Recombinant_Human_Insulin_Like_Growth_Factor_I/Insulin_Like_Growth_Factor_Binding_Protein_3_Administration_on_Body_Composition_and_Physical_Fitness_in_Recreational_Athletes_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-1996 DB - PRIME DP - Unbound Medicine ER -